Suppr超能文献

采用脉冲推挽式透析液流增强溶质清除率,用于 Quanta SC+:一种新型的诊所到家血液透析系统。

Enhancement of solute clearance using pulsatile push-pull dialysate flow for the Quanta SC+: A novel clinic-to-home haemodialysis system.

机构信息

Quanta Dialysis Technologies Ltd, Alcester, Warwickshire, United Kingdom.

Newcastle University, Newcastle upon Tyne, United Kingdom.

出版信息

PLoS One. 2020 Mar 2;15(3):e0229233. doi: 10.1371/journal.pone.0229233. eCollection 2020.

Abstract

BACKGROUND AND OBJECTIVE

The SC+ haemodialysis system developed by Quanta Dialysis Technologies is a small, easy-to-use dialysis system designed to improve patient access to self-care and home haemodialysis. A prototype variant of the standard SC+ device with a modified fluidic management system generating a pulsatile push-pull dialysate flow through the dialyser during use has been developed for evaluation. It was hypothesized that, as a consequence of the pulsatile push-pull flow through the dialyser, the boundary layers at the membrane surface would be disrupted, thereby enhancing solute transport across the membrane, modifying protein fouling and maintaining the surface area available for mass and fluid transport throughout the whole treatment, leading to solute transport (clearance) enhancement compared to normal haemodialysis (HD) operation.

METHODS

The pumping action of the SC+ system was modified by altering the sequence and timings of the valves and pumps associated with the flow balancing chambers that push and pull dialysis fluid to and from the dialyser. Using this unique prototype device, solute clearance performance was assessed across a range of molecular weights in two related series of laboratory bench studies. The first measured dialysis fluid moving across the dialyser membrane using ultrasonic flowmeters to establish the validity of the approach; solute clearance was subsequently measured using fluorescently tagged dextran molecules as surrogates for uraemic toxins. The second study used human blood doped with uraemic toxins collected from the spent dialysate of dialysis patients to quantify solute transport. In both, the performance of the SC+ prototype was assessed alongside reference devices operating in HD and pre-dilution haemodiafiltration (HDF) modes.

RESULTS

Initial testing with fluorescein-tagged dextran molecules (0.3 kDa, 4 kDa, 10 kDa and 20 kDa) established the validity of the experimental pulsatile push-pull operation in the SC+ system to enhance clearance and demonstrated a 10 to 15% improvement above the current HD mode used in clinic today. The magnitude of the observed enhancement compared favourably with that achieved using pre-dilution HDF with a substitution fluid flow rate of 60 mL/min (equivalent to a substitution volume of 14.4 L in a 4-hour session) with the same dialyser and marker molecules. Additional testing using human blood indicated a comparable performance to pre-dilution HDF; however, in contrast with HDF, which demonstrated a gradual decrease in solute removal, the clearance values using the pulsatile push-pull method on the SC+ system were maintained over the entire duration of treatment. Overall albumin losses were not different.

CONCLUSIONS

Results obtained using an experimental pulsatile push-pull dialysis flow configuration with an aqueous blood analogue and human blood ex vivo demonstrate an enhancement of solute transport across the dialyser membrane. The level of enhancement makes this approach comparable with that achieved using pre-dilution HDF with a substitution fluid flow rate of 60 mL/min (equivalent to a substitution volume of 14.4 L in a 4-hour session). The observed enhancement of solute transport is attributed to the disruption of the boundary layers at the fluid-membrane interface which, when used with blood, minimizes protein fouling and maintains the surface area.

摘要

背景和目的

由 Quanta Dialysis Technologies 开发的 SC+血液透析系统是一种小型、易于使用的透析系统,旨在提高患者接受自我护理和家庭血液透析的机会。已经开发出一种标准 SC+设备的原型变体,该变体具有经过修改的流体管理系统,在使用过程中通过透析器产生脉动推挽透析液流。假设通过透析器中的脉动推挽流动,膜表面的边界层将被破坏,从而增强跨膜的溶质传递,改变蛋白质污染并在整个治疗过程中保持用于质量和流体传递的表面积,从而导致与普通血液透析 (HD) 操作相比,溶质传递(清除率)增强。

方法

通过改变与推动和拉动透析液进出透析器的流量平衡腔相关的阀和泵的顺序和时间来修改 SC+系统的泵送动作。使用这种独特的原型设备,在两项相关的实验室台架研究中,评估了一系列分子量的溶质清除性能。第一项使用超声波流量计测量穿过透析器膜的透析液流动,以验证该方法的有效性;随后使用荧光标记的葡聚糖分子作为尿毒症毒素的替代品来测量溶质清除率。第二项研究使用掺杂有尿毒症毒素的人血液,这些毒素从透析患者的废透析液中收集,以定量溶质传递。在这两项研究中,评估了 SC+原型设备与在 HD 和预稀释血液透析滤过 (HDF) 模式下运行的参考设备的性能。

结果

最初使用荧光标记的葡聚糖分子(0.3 kDa、4 kDa、10 kDa 和 20 kDa)进行测试,该测试建立了 SC+系统中实验性脉动推挽操作增强清除率的有效性,并证明与当今临床使用的当前 HD 模式相比,清除率提高了 10% 至 15%。与使用替代液流速为 60 毫升/分钟(相当于 4 小时治疗过程中 14.4 升的替代量)的预稀释 HDF 相比,观察到的增强幅度相当有利,并且使用相同的透析器和标记分子。使用人血液进行的额外测试表明与预稀释 HDF 具有相当的性能;然而,与 HDF 不同,HDF 的溶质去除逐渐减少,使用 SC+系统的脉动推挽方法的清除值在整个治疗过程中保持不变。白蛋白总体损失没有差异。

结论

使用具有水性血液类似物和人血的实验性脉动推挽透析流动配置获得的结果表明,跨透析器膜的溶质传递得到增强。增强水平使这种方法与使用替代液流速为 60 毫升/分钟(相当于 4 小时治疗过程中 14.4 升的替代量)的预稀释 HDF 相当。观察到的溶质传递增强归因于流体-膜界面处边界层的破坏,当与血液一起使用时,边界层会最小化蛋白质污染并保持表面积。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b745/7051047/01c9daca9948/pone.0229233.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验